Souped-up immune cells catch even disguised HIV

By Maggie Fox, Health and Science Editor

WASHINGTON (Reuters) - Genetically engineered immune cells can spot the AIDS virus even when it tries to disguise itself, offering a potential new way to treat the incurable infection, researchers reported on Sunday.

The killer T-cells, dubbed “assassin” cells, were able to recognize other cells infected by HIV and slow the spread of the virus in lab dishes.

If the approach works in people, it might provide a new route of treating infection with the deadly human immunodeficiency virus, the researchers in the United States and Britain said.

“Billions of these anti-HIV warriors can be generated in two weeks,” said Angel Varela-Rohena of the University of Pennsylvania, who helped lead the study.

In a second, unrelated report, researchers testing Dutch biotechnology firm Crucell NV’s experimental AIDS vaccine said it prevented infection in six monkeys.

The animals were infected with a monkey version of HIV called SIV, and the vaccine used a virus that is dangerous to use in humans, so it is not ready for human tests.

But, writing in the journal Nature, Dr. Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston and colleagues said it shows there is still hope for developing a vaccine against AIDS.

The AIDS virus, which infects 33 million people globally, is especially hard to fight. Like all viruses, it hijacks cells in its victims, forcing them to become little viral factories and make more virus.


HIV is even more insidious, attacking immune system cells called CD4 T cells, which help mount a defense. It can also disguise itself to escape CD8 killer cells, also known as cytotoxic T lymphocytes or CTLs.

“CTLs are crucial for the control of HIV infection. Unfortunately, HIV has an arsenal of mutational and nonmutational strategies that aid it in escaping from the CTL response mounted against it by its host,” the researchers wrote in their report, published in the journal Nature Medicine.

One good defense allows HIV to hide a protein called HLA-I-associated antigen.

Varela-Rohena and colleagues took T-cells from an HIV patient and created a genetically engineered version that recognizes this deception.

“It is possible to improve on nature when it comes to preventing HIV CTL escape,” they wrote.

Not only could the engineered T-cells see HIV strains that had escaped detection by natural T-cells, “but the engineered T cells responded in a much more vigorous fashion so that far fewer T-cells were required to control infection,” Penn’s James Riley, who also worked on the study, said in a statement.  Continued…


Related Posts:

By Julie Steenhuysen CHICAGO (Reuters) - An experimental drug cured guinea pigs infected with a fatal hemorrhagic fever virus, raising hope for its use in a broad range of viral diseases including influenza, hepatitis C, HIV, Ebola and others, U.S. researchers said on Sunday. “This is a whole new strategy for making antiviral drugs,” said Dr. Philip

Full Post: Inside-out cells offer target for antiviral drugs

By Andrew Quinn WASHINGTON (Reuters) - A global AIDS vaccine conference this week will seek fresh strategies against the HIV virus, with experts weighing the value of basic laboratory research against large-scale human clinical trials after a string of disappointments. Approaches focusing on “neutralizing antibodies” that would allow the human immune system to block infection completely, are

Full Post: AIDS vaccine focus shifts after disappointments

By Laura MacInnis GENEVA (Reuters) - The body’s initial response to contracting HIV could provide the answers scientists need to develop a vaccine for the AIDS-causing virus, a Nobel-winning expert said on Monday. The AIDS epidemic has killed about 25 million people, and about 33 million worldwide are now infected with HIV. Cocktails of drugs can control

Full Post: First days after HIV infection may hold vaccine key

By Wendell Roelf CAPE TOWN (Reuters) - A U.S. recession could cut AIDS funding and impede the drive to find a vaccine for the disease, a senior official with a group spearheading vaccine research said on Tuesday. The United States is the center of AIDS vaccine research. Its government contributed $659 million, or 69 percent of the

Full Post: U.S. downturn could hurt AIDS vaccine drive: group

BERLIN (Reuters) - A bone marrow transplant using stem cells from a donor with natural genetic resistance to the AIDS virus has left an HIV patient free of infection for nearly two years, German researchers. The patient, an American living in Berlin, was infected with the human immunodeficiency virus that causes AIDS and also had leukemia.

Full Post: Bone marrow transplant suppresses AIDS in patient

Site Navigation

Most Read